444 related articles for article (PubMed ID: 35090594)
1. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S; Koyama S; Itahashi K; Tanegashima T; Lin YT; Togashi Y; Kamada T; Irie T; Okumura G; Kono H; Ito D; Fujii R; Watanabe S; Sai A; Fukuoka S; Sugiyama E; Watanabe G; Owari T; Nishinakamura H; Sugiyama D; Maeda Y; Kawazoe A; Yukami H; Chida K; Ohara Y; Yoshida T; Shinno Y; Takeyasu Y; Shirasawa M; Nakama K; Aokage K; Suzuki J; Ishii G; Kuwata T; Sakamoto N; Kawazu M; Ueno T; Mori T; Yamazaki N; Tsuboi M; Yatabe Y; Kinoshita T; Doi T; Shitara K; Mano H; Nishikawa H
Cancer Cell; 2022 Feb; 40(2):201-218.e9. PubMed ID: 35090594
[TBL] [Abstract][Full Text] [Related]
2. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
5. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
Front Immunol; 2021; 12():654749. PubMed ID: 33936081
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
Yoshida K; Okamoto M; Sasaki J; Kuroda C; Ishida H; Ueda K; Ideta H; Kamanaka T; Sobajima A; Takizawa T; Tanaka M; Aoki K; Uemura T; Kato H; Haniu H; Saito N
BMC Cancer; 2020 Jan; 20(1):25. PubMed ID: 31914969
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
9. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Pham CD; Flores C; Yang C; Pinheiro EM; Yearley JH; Sayour EJ; Pei Y; Moore C; McLendon RE; Huang J; Sampson JH; Wechsler-Reya R; Mitchell DA
Clin Cancer Res; 2016 Feb; 22(3):582-95. PubMed ID: 26405194
[TBL] [Abstract][Full Text] [Related]
10. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
11. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ
J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860
[TBL] [Abstract][Full Text] [Related]
12. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
13. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.
Watson MJ; Vignali PDA; Mullett SJ; Overacre-Delgoffe AE; Peralta RM; Grebinoski S; Menk AV; Rittenhouse NL; DePeaux K; Whetstone RD; Vignali DAA; Hand TW; Poholek AC; Morrison BM; Rothstein JD; Wendell SG; Delgoffe GM
Nature; 2021 Mar; 591(7851):645-651. PubMed ID: 33589820
[TBL] [Abstract][Full Text] [Related]
14. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
16. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J; Inozume T; Sax N; Ariyasu R; Ishikawa M; Yamashita K; Kawazu M; Ueno T; Irie T; Tanji E; Morinaga T; Honobe A; Ohnuma T; Yoshino M; Iwata T; Kawase K; Sasaki K; Hanazawa T; Kochin V; Kawamura T; Matsue H; Hino M; Mano H; Suzuki Y; Nishikawa H; Togashi Y
Cell Rep; 2022 Feb; 38(5):110331. PubMed ID: 35108529
[TBL] [Abstract][Full Text] [Related]
19. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
